Financials & Filings Q1 2024 GlycoMimetics Corporate Update Call GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Form 10-Q Proxy Statements Date Filed View Apr 01, 2024 View HTML 0001558370-24-004448.pdf 0001558370-24-004448.xls Mar 22, 2024 View HTML 0001558370-24-003788.pdf 0001558370-24-003788.xls Form 10-K Date Filed View Apr 01, 2024 View HTML 0001558370-24-004451.pdf Mar 27, 2024 View HTML 0001558370-24-004013.pdf 0001558370-24-004013.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA Form 10-Q Date Filed View May 09, 2024 View HTML 0001558370-24-007632.pdf 0001558370-24-007632.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA Nov 03, 2023 View HTML 0001558370-23-017505.pdf 0001558370-23-017505.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA